The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
暂无分享,去创建一个
[1] D. Mallardo,et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer , 2020, Nature Communications.
[2] Koichi Inoue,et al. Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors , 2020, JAMA network open.
[3] D. Malone,et al. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma , 2020, JAMA network open.
[4] B. Erstad,et al. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis , 2020, Frontiers in Oncology.
[5] K. Leroy,et al. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study , 2020, Cancers.
[6] James X. Sun,et al. Principles of Targeted Therapy for Melanoma. , 2020, The Surgical clinics of North America.
[7] C. Garrido,et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients , 2020, Journal of extracellular vesicles.
[8] I. Kotsianidis,et al. Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist , 2019, eLife.
[9] D. Pardoll,et al. Mechanisms regulating PD-L1 expression on tumor and immune cells , 2019, Journal of Immunotherapy for Cancer.
[10] Lingxiang Mao,et al. The role of exosomal PD-L1 in tumor progression and immunotherapy , 2019, Molecular Cancer.
[11] I. Osman,et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients , 2019, Genome Medicine.
[12] B. Neyns,et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy , 2019, Journal of Translational Medicine.
[13] Xianhe Xie,et al. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors , 2019, Cancer investigation.
[14] P. Zhang,et al. Gut microbiome and cancer immunotherapy. , 2019, Cancer letters.
[15] S. Aamdal,et al. Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma , 2019, Clinical and experimental immunology.
[16] Ryohei Katayama,et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer , 2019, The Journal of experimental medicine.
[17] Ni Zhang,et al. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. , 2019, Immunotherapy.
[18] D. Coit,et al. High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy , 2019, Cancer.
[19] F. Garrido. HLA Class-I Expression and Cancer Immunotherapy. , 2019, Advances in experimental medicine and biology.
[20] P. Hammerman,et al. Identification and characterization of an alternative cancer-derived PD-L1 splice variant , 2019, Cancer Immunology, Immunotherapy.
[21] S. Ranque,et al. Microbiome and the immune system: From a healthy steady-state to allergy associated disruption , 2018, Human Microbiome Journal.
[22] S. M. Toor,et al. Immune checkpoint inhibitors: recent progress and potential biomarkers , 2018, Experimental & Molecular Medicine.
[23] Z. Guo. The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer) , 2018, BMC Cancer.
[24] I. Melero,et al. Cytokines in clinical cancer immunotherapy , 2018, British Journal of Cancer.
[25] Edmond J. Breen,et al. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy , 2018, Clinical Cancer Research.
[26] P. Ascierto,et al. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study , 2018, Cancer Immunology, Immunotherapy.
[27] Minshan Chen,et al. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma , 2018, Journal of Cancer Research and Clinical Oncology.
[28] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[29] Y. Hosomi,et al. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small‐cell Lung Cancer , 2018, Clinical lung cancer.
[30] David M. Woods,et al. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma , 2018, Clinical Cancer Research.
[31] I. Gheorghe,et al. Aspects of Gut Microbiota and Immune System Interactions in Infectious Diseases, Immunopathology, and Cancer , 2018, Front. Immunol..
[32] N. Girard,et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy , 2018, Nature Reviews Clinical Oncology.
[33] D. Jackson,et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma , 2018, Science Translational Medicine.
[34] G. Madonna,et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab , 2018, Journal of Immunotherapy for Cancer.
[35] Y. Fujisawa,et al. Baseline neutrophil to lymphocyte ratio combined with serum LDH level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population , 2018 .
[36] C. Garbe,et al. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies , 2018, British Journal of Cancer.
[37] Wei Zhang,et al. Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response , 2018, Nature.
[38] P. Soares,et al. Melanoma treatment in review , 2018, ImmunoTargets and therapy.
[39] T. Gambichler,et al. Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single‐centre analysis , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[40] L. Koenderman,et al. Neutrophil phenotypes in health and disease , 2018, European journal of clinical investigation.
[41] R. Scolyer,et al. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies , 2018, JAMA oncology.
[42] J. Wolchok,et al. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab , 2018, Clinical Cancer Research.
[43] K. Kabashima,et al. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations , 2018, Front. Oncol..
[44] Kongming Wu,et al. Gut microbiome modulates efficacy of immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.
[45] P. Rutkowski,et al. Immunotherapy of melanoma , 2018, Contemporary oncology.
[46] J. Wolchok,et al. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma , 2018, Cancer medicine.
[47] C. Rosales. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? , 2018, Front. Physiol..
[48] Laurence Zitvogel,et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.
[49] E. Le Chatelier,et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.
[50] Riyue Bao,et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.
[51] K. Flaherty,et al. Mechanisms of resistance to immune checkpoint inhibitors , 2018, British Journal of Cancer.
[52] Jeffrey E Gershenwald,et al. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.
[53] G. Long,et al. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice , 2017, Current opinion in oncology.
[54] A. Ribas,et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) , 2017, The Lancet.
[55] F. Hirsch,et al. MHC class II expression in lung cancer. , 2017, Lung cancer.
[56] E. Frenkel,et al. Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients1 , 2017, Neoplasia.
[57] D. Schadendorf,et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.
[58] K. Yaddanapudi,et al. Myeloid‐derived suppressor cells—a new therapeutic target to overcome resistance to cancer immunotherapy , 2017, Journal of leukocyte biology.
[59] J. Li,et al. The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta‐analysis , 2017, Scandinavian journal of immunology.
[60] A. Eggermont,et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[61] J. Lang,et al. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer , 2017, Oncotarget.
[62] A. Giobbie-Hurder,et al. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade , 2017, Cancer Immunology Research.
[63] N. Juge,et al. Introduction to the human gut microbiota , 2017, The Biochemical journal.
[64] J. Madore,et al. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma , 2017, Clinical Cancer Research.
[65] Robert Damoiseaux,et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.
[66] Y. Fujisawa,et al. Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma , 2017, Cancer science.
[67] Y. Fujisawa,et al. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity. , 2017, Journal of dermatological science.
[68] A. Mackiewicz,et al. Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma , 2017, Contemporary oncology.
[69] R. Kiessling,et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma , 2017, Oncotarget.
[70] Y. Hosomi,et al. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. , 2017, Lung cancer.
[71] Jieying Chen,et al. Suppression of T cells by myeloid-derived suppressor cells in cancer. , 2017, Human immunology.
[72] J. Lunceford,et al. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] M. Amagai,et al. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy , 2016, Oncotarget.
[74] A. Enk,et al. Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. , 2016, Immunotherapy.
[75] T. Graeber,et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.
[76] R. Sullivan,et al. Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1. , 2016 .
[77] C. Berking,et al. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab , 2016, Clinical Cancer Research.
[78] F. Greten,et al. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. , 2016, European journal of cancer.
[79] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.
[80] M. Schell,et al. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab , 2016, Cancer Immunology Research.
[81] Yu Shyr,et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy , 2016, Nature Communications.
[82] J. Larkin,et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma , 2016, British Journal of Cancer.
[83] D. Schadendorf,et al. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab , 2016, Clinical Cancer Research.
[84] Wei Jia,et al. The influence of gut microbiota on drug metabolism and toxicity , 2016, Expert opinion on drug metabolism & toxicology.
[85] H. Maillard,et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma , 2016, The British journal of dermatology.
[86] F. Ginhoux,et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.
[87] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[88] D. Raoult,et al. A comprehensive repertoire of prokaryotic species identified in human beings. , 2015, The Lancet. Infectious diseases.
[89] Johnny Lo,et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma , 2015, Oncotarget.
[90] J. Utikal,et al. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab , 2015, Clinical Cancer Research.
[91] P. Marchetti,et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients , 2015, British Journal of Cancer.
[92] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[93] J. Utikal,et al. Elevated chronic inflammatory factors and myeloid‐derived suppressor cells indicate poor prognosis in advanced melanoma patients , 2015, International journal of cancer.
[94] J. Madore,et al. PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials , 2015, Pigment cell & melanoma research.
[95] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[96] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[97] Jeffrey E. Lee,et al. C-reactive protein as a marker of melanoma progression. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] Razelle Kurzrock,et al. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.
[99] J. Wolchok,et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 , 2015, Cell Research.
[100] C. Horak,et al. Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma , 2014, Clinical Cancer Research.
[101] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[102] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[103] J. Taube,et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. , 2014 .
[104] D. Morton,et al. Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels , 2014, Front. Oncol..
[105] J. Taube,et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.
[106] F. Fulciniti,et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma , 2014, Cancer Immunology, Immunotherapy.
[107] Z. Szallasi,et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma , 2014, Cancer Immunology, Immunotherapy.
[108] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[109] J. Kirkwood,et al. Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab , 2014, PloS one.
[110] C. Meyer,et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab , 2014, Cancer Immunology, Immunotherapy.
[111] Eric Vivier,et al. The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide , 2013, Science.
[112] S. Rosso,et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] M. Stratton,et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .
[115] R. Barker,et al. The soluble isoform of CTLA‐4 as a regulator of T‐cell responses , 2013, European journal of immunology.
[116] C. Garbe,et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis , 2012, British Journal of Cancer.
[117] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[118] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[119] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[120] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[121] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[122] Li-hong Lv,et al. Anticancer Drugs Cause Release of Exosomes with Heat Shock Proteins from Human Hepatocellular Carcinoma Cells That Elicit Effective Natural Killer Cell Antitumor Responses in Vitro* , 2012, The Journal of Biological Chemistry.
[123] J. Neefjes,et al. Towards a systems understanding of MHC class I and MHC class II antigen presentation , 2011, Nature Reviews Immunology.
[124] Zhen-hua Hu,et al. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. , 2011, Cytokine.
[125] Taoyong Chen,et al. Chemokine-Containing Exosomes Are Released from Heat-Stressed Tumor Cells via Lipid Raft-Dependent Pathway and Act as Efficient Tumor Vaccine , 2011, The Journal of Immunology.
[126] A. Aboussekhra,et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule , 2010, Breast Cancer Research.
[127] A. Balcerska,et al. Serum soluble interleukin 2 receptor α in human cancer of adults and children: a review , 2008 .
[128] S. Goodman,et al. Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.
[129] A. Mackensen,et al. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.
[130] R. Harpio,et al. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. , 2004, Clinical biochemistry.
[131] G. Dranoff,et al. Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.
[132] D. Ruiter,et al. On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases , 2003, British Journal of Cancer.
[133] Pascale Jeannin,et al. A soluble form of CTLA‐4 generated by alternative splicing is expressed by nonstimulated human T cells , 1999, European journal of immunology.
[134] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.
[135] T. Honjo,et al. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.
[136] K. Koretz,et al. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. , 1991, Cancer research.